

CANCER GENOMICS & PROTEOMICS

Published by the International Institute of Anticancer Research

ISSN (print): 1109-6535; ISSN (online): 1790-6245

Volume 11, 2014

INDEX

Editorial Board

| | |
|---------------------------|--|
| A. Seth | Editor-in-Chief Laboratory of Molecular Pathology, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre and University of Toronto, Toronto, Ontario, Canada |
| J.G. Delinasios | Managing Editor and Executive Publisher International Institute of Anticancer Research, Athens, Greece |
| L.A. Aaltonen | Department of Medical Genetics, University of Helsinki, Finland |
| R. Abagyan | The Scripps Research Institute, La Jolla, CA, USA |
| F. Ahmed | Department of Radiation Oncology, East Carolina University School of Medicine, Greenville, NC, USA |
| D.-T. Bau | Terry Fox Cancer Research Lab, China Medical University Hospital, Taichung, Taiwan |
| B.F.C. Clark | Department of Molecular Biology, University of Aarhus, Denmark |
| R. Clarke | Vincent T. Lombardi Cancer Center, Georgetown University School of Medicine, Washington, DC, USA |
| T. Efferth | Department of Pharmaceutical Biology Institute of Pharmacy and Biochemistry, University of Mainz, Germany |
| J.A. Fernandes-Pol | Metalloproteomics, LLC, Chesterfield, MO, USA |
| C.V. Forst | Department of Genetics and Genomic Sciences, Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, NY, USA |
| D.S. Gerhard | NIH / NCI, Office of Cancer Genomics, Bethesda, MD, USA |
| T.R. Golub | Pediatric Oncology, Dana-Farber Cancer Institute, Cambridge, MA, USA |
| J. Gordon | Department of Neuroscience, Center for Neurovirology, Temple University School of Medicine, Philadelphia, PA, USA |
| J.W. Gray | OHSU Knight Cancer Institute, Biomedical Engineering, Portland, OR, USA |
| C.-H. Heldin | Ludwig Institute for Cancer Research, Uppsala, Sweden |
| J.D. Hoheisel | Deutsches Krebsforschungszentrum, Genome Research and Bioinformatics, Heidelberg, Germany |
| R.P. Huang | RayBiotech, Inc., Norcross, GA, USA |
| T.H.M. Huang | Department of Molecular Medicine/Institute of Biotechnology, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA |
| S.C. Jhanwar | Departments of Pathology and Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA |
| W.G. Jiang | Metastasis and Angiogenesis Research Group, Department of Surgery, Cardiff University School of Medicine, Cardiff, UK |
| V.C. Jordan | Department of Oncology, Lombardi Comprehensive Cancer Center, Washington, DC, USA |
| J. Ju | Translational Research Laboratories, State University of New York, School of Medicine, Stony Brook, NY, USA |
| A. Kallioniemi | Laboratory of Cancer Genetics, Institute of Medical Technology, Tampere University Hospital, Finland |
| O.P. Kallioniemi | Medical Biotechnology Group, VTT Technical Research Centre of Finland, Turku, Finland |
| K. Khalili | College of Science and Technology, Center for Neurovirology and Cancer Biology, Temple University, Philadelphia, PA, USA |
| D.G. Kieback | Department of Obstetrics and Gynecology, Elblandklinikum, Riesa (Dresden), Germany |
| S.D. Kottaridis | Department of Virology, Hellenic Anticancer Institute, Athens, Greece |
| Y. T. Kwon | Department of Biomedical Sciences, College of Medicine, Seoul National University, Seoul, Republic of Korea |
| B. Léylund-Jones | Avera Cancer Institute, Sioux Falls, SD, USA |
| P. Lichter | Deutsches Krebsforschungszentrum, Heidelberg, Germany |
| A. Lindblom | Karolinska Hospital, Department of Molecular Medicine and Surgery, Stockholm, Sweden |
| G. Lubec | Department of Pediatrics, University of Vienna, Austria |
| J. Lyons-Weiler | Department of Pathology, Center for Oncology Informatics, University of Pittsburgh, PA, USA |
| P.J. McCormick | The Center for Functional Genomics, Gen*NY*Sis Center for Excellence in Cancer Genomics, University of Albany, SUNY, Rensselaer, NY, USA |
| J.D. Minna | Hamon Center for Therapeutic Oncology, University of Texas, Southwestern Medical Center at Dallas, TX, USA |
| F. Mitelman | Department of Clinical Genetics, University Hospital, Lund, Sweden |
| C. Nicot | Department of Microbiology, Immunology and Molecular Genetics, University of Kansas Medical Center, Kansas City, KS, USA |

| | |
|-------------------------|--|
| L. O'Driscoll | School of Pharmacy and Pharmaceutical Sciences, Trinity College, Dublin, Ireland |
| I. Pastan | Laboratory of Molecular Biology, NCI, NIH, Bethesda, MD, USA |
| C.D. Platsoucas | College of Sciences, Old Dominion University, Norfolk, VA, USA |
| J. Quackenbush | Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA |
| J.S. Rader | Department of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, WI, USA |
| R.H. Reeves | Department of Physiology, Johns Hopkins University, School of Medicine, Baltimore, MD, USA |
| K.L. Reichelt | Institute of Pediatric Research, The National Hospital, University of Oslo, Norway |
| T. Ried | Center for Cancer Research, Genetics Branch, NCI, NIH, Bethesda, MD, USA |
| G. Rimbach | Institute for Human Nutrition and Food Science, Christian-Albrechts-University, Kiel, Germany |
| K.D. Rodland | Biological Sciences Division, Pacific Northwest National Laboratory, Richland, WA, USA |
| C. Sansom | The School of Crystallography, Birbeck College, University of London, UK |
| N.A. Saunders | Centre for Immunology and Cancer Research, Princess Alexandra Hospital, University of Queensland, Australia |
| B.W. Schäfer | Department of Oncology, University Children's Hospital, Zurich, Switzerland |
| J. Schneider | Universidad Rey Juan Carlos, Facultad de Ciencias de la Salud, Alcorcón (Madrid), Spain |
| O.J. Semmes | Department of Microbiology and Molecular Cell Biology, Eastern Virginia Medical School, Norfolk, VA, USA |
| G.V. Sherbet | University of Newcastle, Merz Court, Department of Electrical and Electronic Engineering, Newcastle-upon-Tyne, UK |
| S. Smith | City of Hope Cancer Center, Department of Cell and Tumor Biology, Duarte, CA, USA |
| J.C. Strefford | Cancer Science Division, Southampton General Hospital, Southampton, UK |
| J.M. Trent | Tgen, Phoenix, AZ, USA |
| G. Tsangaris | Foundation of Biomedical Research of the Academy of Athens, Central Unit of Genomics-Proteomics, Athens, Greece |
| L.-C. Tsui | University of Hong Kong, Hong Kong |
| G.F. Vande Woude | Laboratory of Molecular Oncology, Van Andel Institute, Grand Rapids, MI, USA |
| D.K. Watson | Department of Pathology & Laboratory Medicine, The James E. Clyburn Research Center, Medical University of South Carolina, Charleston, SC, USA |
| U.H. Weidle | Roche Pharma Research and Early Development (pRED), Roche Diagnostics GmbH, Penzberg, Germany |
| A.T. Yeung | Fox Chase Cancer Center, Philadelphia, PA, USA |
| H. Zhang | Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, CT, USA |

Articles in CANCER GENOMICS & PROTEOMICS are regularly indexed in the following bibliographic services: PUBMED, MEDLINE, CAS (Chemical Abstracts Service); BIOLOGICAL ABSTRACTS; EMBASE and BIOBASE; Compendex, GEOBASE; EMBiology; FLUIDEX; Scopus (Elsevier Bibliographic Databases); BIOSIS PREVIEWS; Science Citation Index Expanded (Web of Science); Google Scholar; LEEDS MEDICAL INFORMATION; CSA ILLUMINA (Cambridge Scientific Abstracts, including: Oncogenes & Growth Factors, Genetics, Medical & Pharmaceutical Biotechnology, Bioengineering); All-Russian Institute of Scientific and Technical Information – VINITI Abstracts Journal; PubsHub; Sociedad Iberoamericana de Información Científica (SIIC) Data Bases.

Editorial Office:

International Institute of Anticancer Research
 1st km Kapandritiou-Kalamou Road,
 P.O. Box 22, Kapandriti, Attiki, 19014, Greece.
 Tel: +30 22950 52945, Fax: +30 22950 53389
 e-mail: journals@iiar-anticancer.org. Web: www.iiar-anticancer.org; www.cgp.iiarjournals.org

Manuscripts and correspondence should be addressed to: Dr. John G. Delinasios, Managing Editor, Editorial Office, Cancer Genomics & Proteomics, 1st km Kapandritiou-Kalamou Road, P.O. Box 22, Kapandriti, Attiki, 19014, Greece. Tel: +30 22950 52945, Fax: +30 22950 53389, e-mail: editor@iiar-anticancer.org

Manuscripts from North America may be sent to the Editor-in-Chief, Prof. A. Seth, CGP, Laboratory of Molecular Pathology, Sunnybrook Research Institute, 2075 Bayview Avenue, Room S112a, Toronto, ON, Canada M4N 3M5. Fax: +1 416 480 5737, e-mail: genomics.proteomics@utoronto.ca

Acknowledgements

The following Organisations supported many of the works published in CANCER GENOMICS & PROTEOMICS, Volume 11, 2014.

Albert Hung Foundation, Hong Kong, P.R. China

Breast Cancer Hope Foundation, London, U.K.

Cancer Research Wales, Cardiff, U.K.

Cancer Society, Stockholm, Sweden

China Medical University Hospital, Taichung, Taiwan,
R.O.C.

Desna Robin Charitable Foundation, U.K.

Deutsche Forschungsgemeinschaft (DFG), Bonn, Germany

Epigenomics AG, Berlin, Germany

Genomics of Cancer Fund, Florida Atlantic University
Foundation, Inc., Boca Raton, FL, U.S.A.

Graduate School of Health Sciences, Gunma University,
Maebashi, Gunma, Japan

Howard Hopkins Program, Howard University Cancer
Center, Washington, DC, U.S.A.

Howard University College of Medicine, Washington, DC,
U.S.A.

King Faisal Specialist Hospital and Research Centre,
Riyadh, Saudi Arabia

King Gustav V Jubilee Fund, Stockholm, Sweden

Life Technologies, Darmstadt, Germany

Ministry of Education, Culture, Sports, Science and
Technology, Tokyo, Japan

Ministry of Health and Welfare, Taipei City, Taiwan, R.O.C.

Ministry of Welfare, Labour and Health, Tokyo, Japan

National Cancer Institute, NIH, Bethesda, MD, U.S.A.

National Center of Excellence for Clinical Trial and
Research, Taipei City, Taiwan, R.O.C.

National Institute on Minority Health and Health
Disparities, NIH, Bethesda, MD, U.S.A.

National Institutes of Health, Bethesda, MD, U.S.A.

Norwegian Microarray Consortium (NMC), Oslo, Norway

Pink Revolution Breast Cancer Alliance, Shrewsbury, MA,
U.S.A.

Samsung Biomedical Research Institute, Seoul, Republic of
Korea

Simeon J. Fortin Charitable Foundation, Boston, MA,
U.S.A.

St. David's Foundation, Austin, TX, U.S.A.

Swedish Cancer Society, Stockholm, Sweden

Terry Fox Cancer Research Foundation, Chilliwack, BC,
Canada

Contents, Volume 11, 2014

Number 1

| | |
|---|----|
| Genome-wide Transcriptional Sequencing Identifies Novel Mutations in Metabolic Genes in Human Hepatocellular Carcinoma. D.M. MEERZAMAN, C. YAN, Q.-R. CHEN, M.N. EDMONSON, C.F. SCHAEFER, R.J. CLIFFORD, B.K. DUNN, L. DONG, R.P. FINNEY, C.M. CULTRARO, Y. HU, Z. YANG, C.V. NGUYEN, J.M. KELLEY, S. CAI, H. ZHANG, J. ZHANG, R. WILSON, L. MESSMER, Y.-H. CHUNG, J.A. KIM, N.H. PARK, M.-S. LYU, I.H. SONG, G. KOMATSOUKIS, K.H. BUETOW (<i>Rockville; Bethesda, MD; Memphis, TN, USA; Seoul; Ulsan; Cheon-An, South Korea</i>) | 1 |
| Cilia Gene Expression Patterns in Cancer. M. SHPAK, M.M. GOLDBERG, M.C. COWPERTHWAITTE (<i>Austin, TX, USA</i>) | 13 |
| * Review: Prospects of Bacterial and Plant Protein-based Immunotoxins for Treatment of Cancer. U.H. WEIDLE, G. TIEFENTHALER, C. SCHILLER, E.H. WEISS, G. GEORGES, U. BRINKMANN (<i>Penzberg; Munich, Germany</i>) | 25 |
| Proteomic Analysis of Soft Tissue Tumor Implants Treated with a Novel Polybisphosphonate. A. ALAIYA, J. FOX, S. BOBIS, G. MATIC, Z. SHINWARI, E. BARHOUSH, M. MÁRQUEZ, S. NILSSON, A.R. HOLMBERG (<i>Riyadh, Saudi Arabia; Manchester, UK; Stockholm, Sweden</i>) | 39 |
| MicroRNA-150 Is up-regulated in Extranodal Marginal Zone Lymphoma of MALT Type. N. GEBAUER, J. KUBA, A. SENFT, A. SCHILLERT, V. BERNARD, C. THORNS (<i>Lübeck, Germany</i>) | 51 |

Number 2

| | |
|---|----|
| * Review: Isolation of Stem Cells Using Spheroids from Fresh Surgical Specimen: An Analytic Mini-Review. I. AVITAL, A. STOJADINOVIC, H. WANG, C. MANNION, W.-C. CHO, J. WANG, Y.-G. MAN (<i>Richmond, VA; Hackensack, NJ; Washington, DC, USA; Hangzhou; Hong Kong, P.R. China</i>) | 57 |
| * Review: Proteases as Activators for Cytotoxic Prodrugs in Antitumor Therapy. U.H. WEIDLE, G. TIEFENTHALER, G. GEORGES (<i>Penzberg, Germany</i>) | 67 |
| A Novel Transmembrane Glycoprotein Cancer Biomarker Present in the X Chromosome. A.-P. DELGADO, S. HAMID, P. BRANDAO, R. NARAYANAN (<i>Boca Raton, FL, USA</i>) | 81 |
| Fucoidan-dependent Increased Membrane Components in HepG2 Cells: Effect of Fucoidan Is Not Due to Gene Expression. K. HAYAKAWA, T. NAGAMINE (<i>Tokyo; Gunma Japan</i>) | 93 |

Number 3

| | |
|--|-----|
| Crucial and Novel Cancer Drivers in a Mouse Model of Triple-negative Breast Cancer. J.P.S. JOHNSON, P. KUMAR, M. KOULNIS, M. PATEL, K. SIMIN (<i>Worcester, MA; Bethesda, MD; Scranton, PA, USA; Singapore</i>) | 115 |
| Profiling of Chromosomal Changes in Potentially Malignant and Malignant Oral Mucosal Lesions from South and South-East Asia Using Array-comparative Genomic Hybridization. M.L.S. LUNDE, E. ROMAN, S. WARNAKULASURIYA, R.I. MEHROTRA, J. LARANNE, E.N. VASSTRAND, S.O. IBRAHIM (<i>Bergen, Norway; London, UK; Allahabad, India; Tampere, Finland</i>) | 127 |

Target Genes of Recurrent Chromosomal Amplification and Deletion in Urothelial Carcinoma. M. WEILANDT, A. KOCH, H. RIEDER, R. DEENEN, H. SCHWENDER, G. NIEGISCHE, W.A. SCHULZ (*Düsseldorf, Germany*)..... 141

Review: Structure and Role of WASP and WAVE in Rho GTPase Signalling in Cancer. J. LANE, T. MARTIN, H.P. WEEKS, W.G. JIANG (*Cardiff, UK*)..... 155

Number 4

* Review: Current State of mTOR Targeting in Human Breast Cancer. U. WAZIR, A. WAZIR, Z.S. KHANZADA, W.G. JIANG, A.K. SHARMA, K. MOKBEL (*London; Cardiff, Wales, UK; Karachi, Pakistan*) 167

The Metastasis Suppressor NME1 Regulates Expression of Genes Linked to Metastasis and Patient Outcome in Melanoma and Breast Carcinoma. J.R. MCCORKLE, M.K. LEONARD, S.D. KRANER, E.M. BLALOCK, D. MA, S.G. ZIMMER, D.M. KAETZEL (*Memphis, TN; Baltimore, MD; Lexington, KY; Iowa City, IA, USA*) 175

Comparative Proteomic Analysis Reveals Growth Inhibition by 3-*N*-alkyloxyestradiol Derivatives (SERM) in Prostate Cancer Cells. J.E. GREEN, J.S. COOPERWOOD, E. TAKA, K.F. SOLIMAN, C.B. GOODMAN, R.R. REAMS (*Tallahassee, FL, USA*)..... 195

Open Reading Frames Associated with Cancer in the Dark Matter of the Human Genome. A.P. DELGADO, P. BRANDAO, M.J. CHAPADO, S. HAMI, R. NARAYANAN (*Boca Raton, FL, USA*) 201

Erratum 215

Number 5

Electrophoretic Characterization of the Mammalian Nuclear Matrix Proteome, Nuclear Envelope, Nucleoli and Covalently Bound ADP-Ribose Polymers: Potential Applications to Cancer. X.G. ARANDA, R.G. RACHO, G. PACHECO-RODRÍGUEZ, R. ÁLVAREZ-GONZÁLEZ (*Fort Worth, TX, USA*)..... 217

Review: Tumor Interstitial Fluid: Proteomic Determination as a Possible Source of Biomarkers. G. BARONZIO, G. PARMAR, M. BARONZIO, M. KISELEVSKY (*Milan, Terni, Italy; Fort Langley, BC, Canada; Moscow, Russia*) 225

Modulation of Liver-Intestine Cadherin (Cadherin 17) Expression, ERK Phosphorylation and WNT Signaling in EPHB6 Receptor-expressing MDA-MB-231 Cells. L. BHUSHAN, N. TAVITIAN, D. DEY, Z. TUMUR, C. PARSA, R.P. KANDPAL (*Pomona, CA, USA*) 239

Analysis of *SHOX2* Methylation as an Aid to Cytology in Lung Cancer Diagnosis. P. ILSE, S. BIESTERFELD, N. POMJANSKI, C. WROBEL, M. SCHRAMM (*Düsseldorf, Germany*)..... 251

Transcriptome Analysis of CD133-positive Stem Cells and Prognostic Value of Survivin in Colorectal Cancer. S.T. KIM, I. SOHN, I.G. DO, J. JANG, S.H. KIM, S.H. JUNG, J.O. PARK, Y.S. PARK, A. TALASAZ, J. LEE, H.C. KIM (*Seoul, Republic of Korea; Stanford, CA, USA*) 259

Number 6

| | |
|---|-----|
| * Review: TCR-MHC/Peptide Interaction: Prospects for New Anti-tumoral Agents. U.H. WEIDLE, G. GEORGES, G. TIEFENTHALER (<i>Penzberg, Germany</i>) | 267 |
| Metabolic Profile of Triple-negative Breast Cancer in African–American Women Reveals Potential Biomarkers of Aggressive Disease. Y.M. KANAAN, B.P. SAMPEY, D. BEYENE, A.K. SNAKULA, T.J. NAAB, L.J. RICKS-SANTI, S. DASI, A. DAY, K.W. BLACKMAN, W. FREDERICK, R.L. COPELAND JR, E. GABRIELSON, R.L. DEWITTY JR (<i>Washington, DC; Durham, NC; Cleveland, OH; Hampton, VA; Baltimore, MD, USA</i>) | 279 |
| The Role of Apurinic/Apyrimidinic Endonuclease DNA Repair Gene in Endometriosis. C.-M. HSU, W.-S. CHANG, J.-J. HWANG, J.-Y. WANG, Y.-L. HSIAO, C.-W. TSAI, J.-C. LIU, T.-H. YING, D.-T. BAU (<i>Taichung; Taipei, Taiwan, ROC</i>) | 295 |
| <i>In Silico</i> Comparative Genomic Analysis of Two Non-small Cell Lung Cancer Subtypes and their Potentials for Cancer Classification. J. LI, D. LI, X. WEI, Y. SU (<i>Zhengzhou, PR China</i>) | 303 |
| Index | 311 |
| Reviews in Volume 11, pages: 25, 57, 67, 167, 499. | |

Subject Index

(Figures refer to page numbers)

- Actin, Rho GTPase, WASP, WAVE, polymerisation, cytoskeleton, Cdc42, Rac, review, 155
- Adenovirus, metastasis, metastasis suppressor, melanoma, microarray, NDPK; NM23, NME1, thyroid carcinoma, 175
- Adult stem cells, cellular replenishment, carcinogenesis, spheroid, surgical specimens, review, 57
- Affinity chromatography, nuclear matrix, proteomics, electrophoresis, PhastSystem, lamins, histones, poly(ADP-ribose), boronate resin, epigenetics, nuclear envelope, nucleoli, chromatin, 217
- African-American women, metabolomic, triple-negative breast cancer, 279
- Anthrax toxin, antibody–drug conjugates, antibody-directed enzyme prodrug therapy, cytotoxic receptor ligand(s), granzyme B, probody, thapsigargin, review, 67
- Anthrax toxin, deimmunization, diphthamide, diphtheria toxin, eukaryotic elongation factor 2, pseudomonas exotoxin, proof-of-concept studies, ricin, saporin, ribosome inactivating proteins, review, 25
- Antibody-directed enzyme prodrug therapy, antibody–drug conjugates, Anthrax toxin, cytotoxic receptor ligand(s), granzyme B, probody, thapsigargin, review, 67
- Antibody–drug conjugates, antibody-directed enzyme prodrug therapy, Anthrax toxin, cytotoxic receptor ligand(s), granzyme B, probody, thapsigargin, review, 67
- Antibody-MHC fusion proteins, chimeric antigen receptors, immunological synapse, T-cell receptor, T-cell receptor-based fusion proteins, review, 267
- APC, cytology, bronchial aspirates, DNA methylation, lung cancer, biomarker, quantitative methylation-specific PCR, p16INK4A, RASSF1A, SHOX2, 251
- APEX1, DNA repair, endometriosis, genotype, polymorphism, 295
- Arid, breast cancer, CGH, integrative analysis, tumor suppressor, oncogene, mouse model, triple-negative, Wnt, Myc, Mapk, LCE, 115
- Array-CGH, oral squamous cell carcinoma, oral submucous fibrosis, betel quid, S100A14 SNPs, 127
- Array-CGH, urothelial carcinoma, chromosomal gains, chromosomal losses, gene expression microarray, 141
- Batch analysis, phenome-genome, expression quantitative trait loci, landscape of diseases, genome-wide association, druggable proteome, biomarkers, open reading frames, uncharacterized proteins, cancer association, 201
- Betel quid, oral squamous cell carcinoma, oral submucous fibrosis, array-CGH, S100A14 SNPs, 127
- Biomarker, cytology, bronchial aspirates, DNA methylation, lung cancer, quantitative methylation-specific PCR, APC, p16INK4A, RASSF1A, SHOX2, 251
- Biomarkers, phenome-genome, expression quantitative trait loci, landscape of diseases, genome-wide association, batch analysis, druggable proteome, open reading frames, uncharacterized proteins, cancer association, 201
- Biomarkers, signal peptide, ORF, ‘dark matter’ of the genome, serum protein, uncharacterized proteins, X-chromosome, cell trafficking, vesicular transport, secreted protein, 81
- Biomarkers, tumor interstitial fluid, proteomics, inflammation, review, 225
- Boronate resin, nuclear matrix, proteomics, electrophoresis, PhastSystem, lamins, histones, poly(ADP-ribose), affinity chromatography, epigenetics, nuclear envelope, nucleoli, chromatin, 217
- Breast cancer, CGH, integrative analysis, tumor suppressor, oncogene, mouse model, triple-negative, Wnt, Myc, Arid, Mapk, LCE, 115
- Breast cancer, soft tissue, tumor implants, osteodex, proteomic analysis, 39
- Breast carcinoma, EPHB6, cadherin 17, CDH17, ERK, WNT, β -catenin, GSK3 β , 239
- Breast, mTOR, cancer, rapamycin, PIKK, Rictor, DAPI, review, 167
- Bronchial aspirates, cytology, DNA methylation, lung cancer, biomarker, quantitative methylation-specific PCR, APC, p16INK4A, RASSF1A, SHOX2, 251
- Cadherin 17, EPHB6, CDH17, ERK, WNT, β -catenin, GSK3 β , breast carcinoma, 239
- Cancer association, phenome-genome, expression quantitative trait loci, landscape of diseases, genome-wide association, batch analysis, druggable proteome, biomarkers, open reading frames, uncharacterized proteins, 201
- Cancer stem cells, CD133+, interleukin-4, surviving, 259
- Cancer, mTOR, breast, rapamycin, PIKK, Rictor, DAPI, review, 167
- Cancer, primary cilia, gene expression, patterns, 13
- Carcinogenesis, adult stem cells, cellular replenishment, spheroid, surgical specimens, review, 57
- B-catenin, EPHB6, cadherin 17, CDH17, ERK, WNT, GSK3 β , breast carcinoma, 239
- CD133+, cancer stem cells, interleukin-4, surviving, 259
- Cdc42, Rho GTPase, WASP, WAVE, actin, polymerisation, cytoskeleton, Rac, review, 155
- CDH17, EPHB6, cadherin 17, ERK, WNT, β -catenin, GSK3 β , breast carcinoma, 239
- Cell trafficking, signal peptide, ORF, ‘dark matter’ of the genome, serum protein, uncharacterized proteins, biomarkers, X-chromosome, vesicular transport, secreted protein, 81
- Cellular replenishment, adult stem cells, carcinogenesis, spheroid, surgical specimens, review, 57
- CGH, breast cancer, integrative analysis, tumor suppressor, oncogene, mouse model, triple-negative, Wnt, Myc, Arid, Mapk, LCE, 115
- Chimeric antigen receptors, antibody-MHC fusion proteins, immunological synapse, T-cell receptor, T-cell receptor-based fusion proteins, review, 267

- Chromatin, nuclear matrix, proteomics, electrophoresis, PhastSystem, lamins, histones, poly(ADP-ribose), boronate resin, affinity chromatography, epigenetics, nuclear envelope, nucleoli, 217
- Chromosomal gains, urothelial carcinoma, chromosomal losses, gene expression microarray, array-CGH, 141
- Chromosomal losses, urothelial carcinoma, chromosomal gains, gene expression microarray, array-CGH, 141
- Cytology, bronchial aspirates, DNA methylation, lung cancer, biomarker, quantitative methylation-specific PCR, APC, p16INK4A, RASSF1A, SHOX2, 251
- Cytoskeleton, Rho GTPase, WASP, WAVE, actin, polymerisation, Cdc42, Rac, review, 155
- Cytotoxic receptor ligand(s), antibody–drug conjugates, antibody-directed enzyme prodrug therapy, Anthrax toxin, granzyme B, probody, thapsigargin, review, 67
- DAPI, mTOR, breast, cancer, rapamycin, PIKK, Rictor, review, 167
- ‘Dark matter’ of the genome, signal peptide, ORF, serum protein, uncharacterized proteins, biomarkers, X-chromosome, cell trafficking, vesicular transport, secreted protein, 81
- De-anchoring, direct micro-sequencing, proteomics, protein determination, invaded microbes, membrane protein, hydrophobicity, liver cancer, HCC, HCV, HIV, viral proteins, Ishi-Mozuku, fucoidan, 93
- Deimmunization, anthrax toxin, diphthamide, diphtheria toxin, eukaryotic elongation factor 2, pseudomonas exotoxin, proof-of-concept studies, ricin, saporin, ribosome inactivating proteins, review, 25
- Diphthamide, anthrax toxin, deimmunization, diphtheria toxin, eukaryotic elongation factor 2, pseudomonas exotoxin, proof-of-concept studies, ricin, saporin, ribosome inactivating proteins, review, 25
- Diphtheria toxin, anthrax toxin, deimmunization, diphthamide, eukaryotic elongation factor 2, pseudomonas exotoxin, proof-of-concept studies, ricin, saporin, ribosome inactivating proteins, review, 25
- Direct micro-sequencing, proteomics, protein determination, invaded microbes, membrane protein, hydrophobicity, de-anchoring, liver cancer, HCC, HCV, HIV, viral proteins, Ishi-Mozuku, fucoidan, 93
- DNA methylation, cytology, bronchial aspirates, lung cancer, biomarker, quantitative methylation-specific PCR, APC, p16INK4A, RASSF1A, SHOX2, 251
- DNA repair, APEX1, endometriosis, genotype, polymorphism, 295
- Druggable proteome, phenome-genome, expression quantitative trait loci, landscape of diseases, genome-wide association, batch analysis, biomarkers, open reading frames, uncharacterized proteins, cancer association, 201
- Electrophoresis, nuclear matrix, proteomics, PhastSystem, lamins, histones, poly(ADP-ribose), boronate resin, affinity chromatography, epigenetics, nuclear envelope, nucleoli, chromatin, 217
- Endometriosis, APEX1, DNA repair, genotype, polymorphism, 295
- EPHB6, cadherin 17, CDH17, ERK, WNT, β -catenin, GSK3 β , breast carcinoma, 239
- Epigenetics, nuclear matrix, proteomics, electrophoresis, PhastSystem, lamins, histones, poly(ADP-ribose), boronate resin, affinity chromatography, nuclear envelope, nucleoli, chromatin, 217
- ERK, EPHB6, cadherin 17, CDH17, WNT, β -catenin, GSK3 β , breast carcinoma, 239
- Eukaryotic elongation factor 2, anthrax toxin, deimmunization, diphthamide, diphtheria toxin, pseudomonas exotoxin, proof-of-concept studies, ricin, saporin, ribosome inactivating proteins, review, 25
- Expression quantitative trait loci, phenome-genome, landscape of diseases, genome-wide association, batch analysis, druggable proteome, biomarkers, open reading frames, uncharacterized proteins, cancer association, 201
- Fucoidan, direct micro-sequencing, proteomics, protein determination, invaded microbes, membrane protein, hydrophobicity, de-anchoring, liver cancer, HCC, HCV, HIV, viral proteins, Ishi-Mozuku, 93
- Functional module network analysis, lung adenocarcinoma, squamous cell lung carcinoma, microarray data, support vector machine classifier, 303
- GAPDH, prostate cancer, SERMs, selective estrogen receptor modulators, NCI-60, proteomics, GRP78, triosephosphate isomerase, 195
- Gastritis, microRNA, MALT, lymphoma, malignant transformation, 51
- Gene expression microarray, urothelial carcinoma, chromosomal gains, chromosomal losses, array-CGH, 141
- Gene expression, cancer, primary cilia, patterns, 13
- Gene expression, hepatocellular carcinoma (HCC), RNA-seq, mutation, 1
- Genome-wide association, phenome-genome, expression quantitative trait loci, landscape of diseases, batch analysis, druggable proteome, biomarkers, open reading frames, uncharacterized proteins, cancer association, 201
- Genotype, APEX1, DNA repair, endometriosis, polymorphism, 295
- Granzyme B, antibody–drug conjugates, antibody-directed enzyme prodrug therapy, Anthrax toxin, cytotoxic receptor ligand(s), probody, thapsigargin, review, 67
- GRP78, prostate cancer, SERMs, selective estrogen receptor modulators, NCI-60, proteomics, triosephosphate isomerase, GAPDH, 195
- GSK3 β , EPHB6, cadherin 17, CDH17, ERK, WNT, β -catenin, breast carcinoma, 239
- HCC, direct micro-sequencing, proteomics, protein determination, invaded microbes, membrane protein, hydrophobicity, de-anchoring, liver cancer, HCV, HIV, viral proteins, Ishi-Mozuku, fucoidan, 93
- HCV, direct micro-sequencing, proteomics, protein determination, invaded microbes, membrane protein, hydrophobicity, de-anchoring, liver cancer, HCC, HIV, viral proteins, Ishi-Mozuku, fucoidan, 93
- Hepatocellular carcinoma (HCC), RNA-seq, gene expression, mutation, 1

- Histones, nuclear matrix, proteomics, electrophoresis, PhastSystem, lamins, poly(ADP-ribose), boronate resin, affinity chromatography, epigenetics, nuclear envelope, nucleoli, chromatin, 217
- HIV, direct micro-sequencing, proteomics, protein determination, invaded microbes, membrane protein, hydrophobicity, de-anchoring, liver cancer, HCC, HCV, viral proteins, Ishi-Mozuku, fucoidan, 93
- Hydrophobicity, direct micro-sequencing, proteomics, protein determination, invaded microbes, membrane protein, de-anchoring, liver cancer, HCC, HCV, HIV, viral proteins, Ishi-Mozuku, fucoidan, 93
- Immunological synapse, antibody-MHC fusion proteins, chimeric antigen receptors, T-cell receptor, T-cell receptor-based fusion proteins, review, 267
- Inflammation, tumor interstitial fluid, proteomics, biomarkers, review, 225
- Integrative analysis, breast cancer, CGH, tumor suppressor, oncogene, mouse model, triple-negative, Wnt, Myc, Arid, Mapk, LCE, 115
- Interleukin-4, cancer stem cells, CD133+, surviving, 259
- Invaded microbes, direct micro-sequencing, proteomics, protein determination, membrane protein, hydrophobicity, de-anchoring, liver cancer, HCC, HCV, HIV, viral proteins, Ishi-Mozuku, fucoidan, 93
- Ishi-Mozuku, direct micro-sequencing, proteomics, protein determination, invaded microbes, membrane protein, hydrophobicity, de-anchoring, liver cancer, HCC, HCV, HIV, viral proteins, fucoidan, 93
- Lamins, nuclear matrix, proteomics, electrophoresis, PhastSystem, histones, poly(ADP-ribose), boronate resin, affinity chromatography, epigenetics, nuclear envelope, nucleoli, chromatin, 217
- Landscape of diseases, phenome-genome, expression quantitative trait loci, genome-wide association, batch analysis, druggable proteome, biomarkers, open reading frames, uncharacterized proteins, cancer association, 201
- LCE, breast cancer, CGH, integrative analysis, tumor suppressor, oncogene, mouse model, triple-negative, Wnt, Myc, Arid, Mapk, 115
- Liver cancer, direct micro-sequencing, proteomics, protein determination, invaded microbes, membrane protein, hydrophobicity, de-anchoring, HCC, HCV, HIV, viral proteins, Ishi-Mozuku, fucoidan, 93
- Lung adenocarcinoma, squamous cell lung carcinoma, microarray data, functional module network analysis, support vector machine classifier, 303
- Lung cancer, cytology, bronchial aspirates, DNA methylation, biomarker, quantitative methylation-specific PCR, APC, p16INK4A, RASSF1A, SHOX2, 251
- Lymphoma, microRNA, gastritis, MALT, malignant transformation, 51
- Malignant transformation, microRNA, gastritis, MALT, lymphoma, 51
- MALT, microRNA, gastritis, lymphoma, malignant transformation, 51
- Mapk, breast cancer, CGH, integrative analysis, tumor suppressor, oncogene, mouse model, triple-negative, Wnt, Myc, Arid, LCE, 115
- Melanoma, adenovirus, metastasis, metastasis suppressor, microarray, NDPK; NM23, NME1, thyroid carcinoma, 175
- Membrane protein, direct micro-sequencing, proteomics, protein determination, invaded microbes, hydrophobicity, de-anchoring, liver cancer, HCC, HCV, HIV, viral proteins, Ishi-Mozuku, fucoidan, 93
- Metabolomic, triple-negative breast cancer, African-American women, 279
- Metastasis suppressor, adenovirus, metastasis, melanoma, microarray, NDPK; NM23, NME1, thyroid carcinoma, 175
- Metastasis, adenovirus, metastasis suppressor, melanoma, microarray, NDPK; NM23, NME1, thyroid carcinoma, 175
- Microarray, adenovirus, metastasis, metastasis suppressor, melanoma, NDPK; NM23, NME1, thyroid carcinoma, 175
- Microarray data, lung adenocarcinoma, squamous cell lung carcinoma, functional module network analysis, support vector machine classifier, 303
- MicroRNA, gastritis, MALT, lymphoma, malignant transformation, 51
- Mouse model, breast cancer, CGH, integrative analysis, tumor suppressor, oncogene, triple-negative, Wnt, Myc, Arid, Mapk, LCE, 115
- MTOR, breast, cancer, rapamycin, PIKK, Rictor, DAPI, review, 167
- Mutation, hepatocellular carcinoma (HCC), RNA-seq, gene expression, 1
- Myc, breast cancer, CGH, integrative analysis, tumor suppressor, oncogene, mouse model, triple-negative, Wnt, Arid, Mapk, LCE, 115
- NCI-60, prostate cancer, SERMs, selective estrogen receptor modulators, proteomics, GRP78, triosephosphate isomerase, GAPDH, 195
- NDPK; NM23, adenovirus, metastasis, metastasis suppressor, melanoma, microarray, NME1, thyroid carcinoma, 175
- NME1, adenovirus, metastasis, metastasis suppressor, melanoma, microarray, NDPK; NM23, thyroid carcinoma, 175
- Nuclear envelope, nuclear matrix, proteomics, electrophoresis, PhastSystem, lamins, histones, poly(ADP-ribose), boronate resin, affinity chromatography, epigenetics, nucleoli, chromatin, 217
- Nuclear matrix, proteomics, electrophoresis, PhastSystem, lamins, histones, poly(ADP-ribose), boronate resin, affinity chromatography, epigenetics, nuclear envelope, nucleoli, chromatin, 217
- Nucleoli, nuclear matrix, proteomics, electrophoresis, PhastSystem, lamins, histones, poly(ADP-ribose), boronate resin, affinity chromatography, epigenetics, nuclear envelope, chromatin, 217
- Oncogene, breast cancer, CGH, integrative analysis, tumor suppressor, mouse model, triple-negative, Wnt, Myc, Arid, Mapk, LCE, 115
- Open reading frames, phenome-genome, expression quantitative trait loci, landscape of diseases, genome-wide association, batch analysis, druggable proteome, biomarkers, uncharacterized proteins, cancer association, 201

- Oral squamous cell carcinoma, oral submucous fibrosis, betel quid, array-CGH, S100A14 SNPs, 127
- Oral submucous fibrosis, oral squamous cell carcinoma, betel quid, array-CGH, S100A14 SNPs, 127
- ORF, signal peptide, 'dark matter' of the genome, serum protein, uncharacterized proteins, biomarkers, X-chromosome, cell trafficking, vesicular transport, secreted protein, 81
- Osteodex, soft tissue, tumor implants, proteomic analysis, breast cancer, 39
- P16INK4A, cytology, bronchial aspirates, DNA methylation, lung cancer, biomarker, quantitative methylation-specific PCR, APC, RASSF1A, SHOX2, 251
- Patterns, cancer, primary cilia, gene expression, 13
- PhastSystem, nuclear matrix, proteomics, electrophoresis, lamins, histones, poly(ADP-ribose), boronate resin, affinity chromatography, epigenetics, nuclear envelope, nucleoli, chromatin, 217
- Phenome-genome, expression quantitative trait loci, landscape of diseases, genome-wide association, batch analysis, druggable proteome, biomarkers, open reading frames, uncharacterized proteins, cancer association, 201
- PIKK, mTOR, breast, cancer, rapamycin, Rictor, DAP1, review, 167
- Poly(ADP-ribose), nuclear matrix, proteomics, electrophoresis, PhastSystem, lamins, histones, boronate resin, affinity chromatography, epigenetics, nuclear envelope, nucleoli, chromatin, 217
- Polymerisation, Rho GTPase, WASP, WAVE, actin, cytoskeleton, Cdc42, Rac, review, 155
- Polymorphism, APEX1, DNA repair, endometriosis, genotype, 295
- Primary cilia, cancer, gene expression, patterns, 13
- Probody, antibody–drug conjugates, antibody-directed enzyme prodrug therapy, Anthrax toxin, cytotoxic receptor ligand(s), granzyme B, thapsigargin, review, 67
- Proof-of-concept studies, anthrax toxin, deimmunization, diphthamide, diphtheria toxin, eukaryotic elongation factor 2, pseudomonas exotoxin, ricin, saporin, ribosome inactivating proteins, review, 25
- Prostate cancer, SERMs, selective estrogen receptor modulators, NCI-60, proteomics, GRP78, triosephosphate isomerase, GAPDH, 195
- Protein determination, direct micro-sequencing, proteomics, invaded microbes, membrane protein, hydrophobicity, de-anchoring, liver cancer, HCC, HCV, HIV, viral proteins, Ishi-Mozuku, fucoidan, 93
- Proteomic analysis, soft tissue, tumor implants, osteodex, breast cancer, 39
- Proteomics, direct micro-sequencing, protein determination, invaded microbes, membrane protein, hydrophobicity, de-anchoring, liver cancer, HCC, HCV, HIV, viral proteins, Ishi-Mozuku, fucoidan, 93
- Proteomics, nuclear matrix, electrophoresis, PhastSystem, lamins, histones, poly(ADP-ribose), boronate resin, affinity chromatography, epigenetics, nuclear envelope, nucleoli, chromatin, 217
- Proteomics, prostate cancer, SERMs, selective estrogen receptor modulators, NCI-60, GRP78, triosephosphate isomerase, GAPDH, 195
- Proteomics, tumor interstitial fluid, biomarkers, inflammation, review, 225
- Pseudomonas exotoxin, anthrax toxin, deimmunization, diphthamide, diphtheria toxin, eukaryotic elongation factor 2, proof-of-concept studies, ricin, saporin, ribosome inactivating proteins, review, 25
- Quantitative methylation-specific PCR, cytology, bronchial aspirates, DNA methylation, lung cancer, biomarker, APC, p16INK4A, RASSF1A, SHOX2, 251
- Rac, Rho GTPase, WASP, WAVE, actin, polymerisation, cytoskeleton, Cdc42, review, 155
- Rapamycin, mTOR, breast, cancer, PIKK, Rictor, DAP1, review, 167
- RASSF1A, cytology, bronchial aspirates, DNA methylation, lung cancer, biomarker, quantitative methylation-specific PCR, APC, p16INK4A, SHOX2, 251
- Review, adult stem cells, cellular replenishment, carcinogenesis, spheroid, surgical specimens, 57
- Review, anthrax toxin, deimmunization, diphthamide, diphtheria toxin, eukaryotic elongation factor 2, pseudomonas exotoxin, proof-of-concept studies, ricin, saporin, ribosome inactivating proteins, 25
- Review, antibody–drug conjugates, antibody-directed enzyme prodrug therapy, Anthrax toxin, cytotoxic receptor ligand(s), granzyme B, probody, thapsigargin, 67
- Review, antibody-MHC fusion proteins, chimeric antigen receptors, immunological synapse, T-cell receptor, T-cell receptor-based fusion proteins, 267
- Review, mTOR, breast, cancer, rapamycin, PIKK, Rictor, DAP1, 167
- Review, Rho GTPase, WASP, WAVE, actin, polymerisation, cytoskeleton, Cdc42, Rac, 155
- Review, tumor interstitial fluid, proteomics, biomarkers, inflammation, 225
- Rho GTPase, WASP, WAVE, actin, polymerisation, cytoskeleton, Cdc42, Rac, review, 155
- Ribosome inactivating proteins, anthrax toxin, deimmunization, diphthamide, diphtheria toxin, eukaryotic elongation factor 2, pseudomonas exotoxin, proof-of-concept studies, ricin, saporin, review, 25
- Ricin, anthrax toxin, deimmunization, diphthamide, diphtheria toxin, eukaryotic elongation factor 2, pseudomonas exotoxin, proof-of-concept studies, saporin, ribosome inactivating proteins, review, 25
- Rictor, mTOR, breast, cancer, rapamycin, PIKK, DAP1, review, 167
- RNA-seq, hepatocellular carcinoma (HCC), gene expression, mutation, 1
- S100A14 SNPs, oral squamous cell carcinoma, oral submucous fibrosis, betel quid, array-CGH, 127
- Saporin, anthrax toxin, deimmunization, diphthamide, diphtheria toxin, eukaryotic elongation factor 2, pseudomonas exotoxin, proof-of-concept studies, ricin, ribosome inactivating proteins, review, 25

- Secreted protein, signal peptide, ORF, 'dark matter' of the genome, serum protein, uncharacterized proteins, biomarkers, X-chromosome, cell trafficking, vesicular transport, 81
- Selective estrogen receptor modulators, prostate cancer, SERMs, NCI-60, proteomics, GRP78, triosephosphate isomerase, GAPDH, 195
- SERMs, prostate cancer, selective estrogen receptor modulators, NCI-60, proteomics, GRP78, triosephosphate isomerase, GAPDH, 195
- Serum protein, signal peptide, ORF, 'dark matter' of the genome, uncharacterized proteins, biomarkers, X-chromosome, cell trafficking, vesicular transport, secreted protein, 81
- SHOX2, cytology, bronchial aspirates, DNA methylation, lung cancer, biomarker, quantitative methylation-specific PCR, APC, p16INK4A, RASSF1A, 251
- Signal peptide, ORF, 'dark matter' of the genome, serum protein, uncharacterized proteins, biomarkers, X-chromosome, cell trafficking, vesicular transport, secreted protein, 81
- Soft tissue, tumor implants, osteodex, proteomic analysis, breast cancer, 39
- Spheroid, adult stem cells, cellular replenishment, carcinogenesis, surgical specimens, review, 57
- Squamous cell lung carcinoma, lung adenocarcinoma, microarray data, functional module network analysis, support vector machine classifier, 303
- Support vector machine classifier, lung adenocarcinoma, squamous cell lung carcinoma, microarray data, functional module network analysis, 303
- Surgical specimens, adult stem cells, cellular replenishment, carcinogenesis, spheroid, review, 57
- Surviving, cancer stem cells, CD133+, interleukin-4, 259
- T-cell receptor, antibody-MHC fusion proteins, chimeric antigen receptors, immunological synapse, T-cell receptor-based fusion proteins, review, 267
- T-cell receptor-based fusion proteins, antibody-MHC fusion proteins, chimeric antigen receptors, immunological synapse, T-cell receptor, review, 267
- Thapsigargin, antibody-drug conjugates, antibody-directed enzyme prodrug therapy, Anthrax toxin, cytotoxic receptor ligand(s), granzyme B, probody, review, 67
- Thyroid carcinoma, adenovirus, metastasis, metastasis suppressor, melanoma, microarray, NDPK, NM23, NME1, 175
- Triosephosphate isomerase, prostate cancer, SERMs, selective estrogen receptor modulators, NCI-60, proteomics, GRP78, GAPDH, 195
- Triple-negative, breast cancer, CGH, integrative analysis, tumor suppressor, oncogene, mouse model, Wnt, Myc, Arid, Mapk, LCE, 115
- Triple-negative breast cancer, metabolomic, African-American women, 279
- Tumor implants, soft tissue, osteodex, proteomic analysis, breast cancer, 39
- Tumor interstitial fluid, proteomics, biomarkers, inflammation, review, 225
- Tumor suppressor, breast cancer, CGH, integrative analysis, oncogene, mouse model, triple-negative, Wnt, Myc, Arid, Mapk, LCE, 115
- Uncharacterized proteins, phenome-genome, expression quantitative trait loci, landscape of diseases, genome-wide association, batch analysis, druggable proteome, biomarkers, open reading frames, cancer association, 201
- Uncharacterized proteins, signal peptide, ORF, 'dark matter' of the genome, serum protein, biomarkers, X-chromosome, cell trafficking, vesicular transport, secreted protein, 81
- Urothelial carcinoma, chromosomal gains, chromosomal losses, gene expression microarray, array-CGH, 141
- Vesicular transport, signal peptide, ORF, 'dark matter' of the genome, serum protein, uncharacterized proteins, biomarkers, X-chromosome, cell trafficking, secreted protein, 81
- Viral proteins, direct micro-sequencing, proteomics, protein determination, invaded microbes, membrane protein, hydrophobicity, de-anchoring, liver cancer, HCC, HCV, HIV, Ishi-Mozuku, fucoidan, 93
- WASP, Rho GTPase, WAVE, actin, polymerisation, cytoskeleton, Cdc42, Rac, review, 155
- WAVE, Rho GTPase, WASP, actin, polymerisation, cytoskeleton, Cdc42, Rac, review, 155
- Wnt, breast cancer, CGH, integrative analysis, tumor suppressor, oncogene, mouse model, triple-negative, Myc, Arid, Mapk, LCE, 115
- WNT, EPHB6, cadherin 17, CDH17, ERK, β -catenin, GSK3 β , breast carcinoma, 239
- X-chromosome, signal peptide, ORF, 'dark matter' of the genome, serum protein, uncharacterized proteins, biomarkers, cell trafficking, vesicular transport, secreted protein, 81

Authors Index

(Figures refer to page numbers)

- Alaiya A, 39
 Álvarez-González R, 217
 Aranda XG, 217
 Avital I, 57
 Barhoush E, 39
 Baronzio G, 225
 Baronzio M, 225
 Bau D-T, 295
 Bernard V, 51
 Beyene D, 279
 Bhushan L, 239
 Biesterfeld S, 251
 Blackman KW, 279
 Blalock EM, 175
 Bobis S, 39
 Brandao P, 81, 201
 Brinkmann U, 25
 Buetow KH, 1
 Cai S, 1
 Chang W-S, 295
 Chapado MJ, 201
 Chen Q-R, 1
 Cho W-C, 57
 Chung Y-H, 1
 Clifford RJ, 1
 Cooperwood JS, 195
 Copeland Jr RL, 279
 Cowperthwaite MC, 13
 Cultraro CM, 1
 Dasi S, 279
 Day A, 279
 Deenen R, 141
 Delgado AP, 81, 201
 DeWitty Jr RL, 279
 Dey D, 239
 Do IG, 259
 Dong L, 1
 Dunn BK, 1
 Edmonson MN, 1
 Finney RP, 1
 Fox J, 39
 Frederick W, 279
 Gabrielson E, 279
 Gebauer N, 51
 Georges G, 25, 67, 267
 Goldberg MM, 13
 Goodman CB, 195
 Green JE, 195
 Hami S, 201
 Hamid S, 81
 Hayakawa K, 93
 Holmberg AR, 39
 Hsiao Y-L, 295
 Hsu C-M, 295
 Hu Y, 1
 Hwang J-J, 295
 Ibrahim SO, 127
 Ilse P, 251
 Jang J, 259
 Jiang WG, 155, 167
 Johnson JPS, 115
 Jung SH, 259
 Kaetzel DM, 175
 Kanaan YM, 279
 Kandpal RP, 239
 Kelley JM, 1
 Khanzada ZS, 167
 Kim HC, 259
 Kim JA, 1
 Kim SH, 259
 Kim ST, 259
 Kiselevsky M, 225
 Koch A, 141
 Komatsoulis G, 1
 Koulnis M, 115
 Kraner SD, 175
 Kuba J, 51
 Kumar P, 115
 Lane J, 155
 Laranne J, 127
 Lee J, 259
 Leonard MK, 175
 Li D, 303
 Li J, 303
 Liu J-C, 295
 Lunde MLS, 127
 Lyu M-S, 1
 Ma D, 175
 Man Y-G, 57
 Mannion C, 57
 Márquez M, 39
 Martin T, 155
 Matic G, 39
 McCorkle JR, 175
 Meerzaman DM, 1
 Mehrotra RI, 127
 Messmer L, 1
 Mokbel K, 167
 Naab TJ, 279
 Nagamine T, 93
 Narayanan R, 81, 201
 Nguyen CV, 1
 Niegisch G, 141
 Nilsson S, 39
 Pacheco-Rodríguez G, 217
 Park JO, 259
 Park NH, 1
 Park YS, 259
 Parmar G, 225
 Parsa C, 239
 Patel M, 115
 Pomjanski N, 251
 Racho RG, 217
 Reams RR, 195
 Rickssanti LJ, 279
 Rieder H, 141
 Roman E, 127
 Sampey BP, 279
 Schaefer CF, 1
 Schiller C, 25
 Schillert A, 51
 Schramm M, 251
 Schulz WA, 141
 Schwender H, 141
 Senft A, 51
 Sharma AK, 167
 Shinwari Z, 39
 Shpak M, 13
 Simin K, 115
 Snakula AK, 279
 Sohn I, 259
 Soliman KF, 195
 Song IH, 1
 Stojadinovic A, 57
 Su Y, 303
 Taka E, 195
 Talasaz A, 259
 Tavitian N, 239
 Thorns C, 51
 Tiefenthaler G, 25, 67, 267
 Tsai C-W, 295
 Tumur Z, 239
 Vasstrand EN, 127
 Wang H, 57
 Wang J, 57
 Wang J-Y, 295
 Warnakulasuriya S, 127
 Wazir A, 167
 Wazir U, 167
 Weeks HP, 155
 Wei X, 303
 Weidle UH, 25, 67, 267
 Weilandt M, 141
 Weiss EH, 25
 Wilson R, 1
 Wrobel C, 251
 Yan C, 1
 Yang Z, 1
 Ying T-H, 295
 Zhang H, 1
 Zhang J, 1
 Zimmer SG, 175

Erratum

Volume 10, No. 5, page 233: The name of the second Author should read:

SHIN NISHIUMI²

CANCER GENOMICS & PROTEOMICS supports (a) the aims and the research projects of the INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH (IIAR, Kapandriti, Attiki, Greece) and (b) the organization of the International Conferences of Anticancer Research.

CANCER GENOMICS & PROTEOMICS appears online with Stanford University HighWire Press.

For more information about CANCER GENOMICS & PROTEOMICS, IIAR and the Conferences please visit our websites: www.iiar-anticancer.org, www.cgp.iiarjournals.org

Publication Data: CANCER GENOMICS & PROTEOMICS (CGP) is published online-only with open access bimonthly. Each annual volume contains six issues. Annual Authors and Subject Indexes are included in the sixth issue of each volume.

Copyright: Once a manuscript has been published in CGP, which is a copyrighted publication, the legal ownership of all published parts of the paper passes from the Author to the Journal.

Manuscripts, correspondence, requests for sample copies and orders should be addressed to: Dr. John G. Delinasios, Managing Editor, Editorial Office, Cancer Genomics & Proteomics, 1st km Kapandritiou-Kalamou Road, P.O. Box 22, Kapandriti, Attiki, 19014, Greece. Tel: +30 22950 52945, Fax: +30 22950 53389, e-mail: journals@iiar-anticancer.org (Editorial Office), editor@iiar-anticancer.org (Managing Editor).

Manuscripts from North America may be sent to the Editor-in-Chief, Prof. A. Seth, CGP, Laboratory of Molecular Pathology, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, ON, Canada M4N 3M5. Fax: 416 978 5956, e-mail: genomics.proteomics@utoronto.ca

Annual Subscription. CANCER GENOMICS & PROTEOMICS is converted to an online-only open access journal from January 2014 (Volume 11)

The Editors and Publishers of the journal CANCER GENOMICS & PROTEOMICS accept no responsibility for the opinions expressed by the contributors or for the content of the advertisements appearing therein.